教員情報 - 長谷川　幸清

教員情報トップぺージ

ホームページ

研究課題・受託研究・科研費

学術雑誌

学会発表

専門医・専門性キーワード

（最終更新日：2026-07-16 13:03:08）

  ハセガワ　コウセイ   HASEGAWA Kosei
  長谷川　幸清
   所属   埼玉医科大学医学部国際医療センター　産婦人科（婦人科腫瘍科）

職種教授

■ ホームページ

http://www.saitama-med.ac.jp/kokusai/fujinshuyo/

https://www.researchgate.net/profile/Kosei_Hasegawa/publications

■ 研究課題・受託研究・科研費

1.	2020/04～	抗レトロウィルス薬のドラッグリバーバシングによるLINE１発現子宮体癌の治療戦略若手研究（B)
2.	2020/04～2021/03	ヒト上皮性腫瘍の発生・進展機構の解明と新規治療標的の同定
3.	2019/04～2023/03	卵巣癌の個別化治療を目指した免疫プロファイルに基づく包括的バイオマーカーの開発基盤研究(C)
4.	2018/04～2021/03	卵巣癌における、低酸素関連因子の発現からみた組織型の意義：科学療法抵抗性の分別化基盤研究(C)
5.	2016/04～2019/03	卵巣明細胞腺癌におけるネオ抗原および局所免疫応答の統合的解析基盤研究(C)

■ 学術雑誌

1.	学術雑誌(総説)	Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer. 2013/09
2.	学術雑誌(総説)	Clinical trials of neoadjuvant chemotherapy for ovarian cancer: what do we gain after an EORTC trial and after two additional ongoing trials are completed? 2013/06
3.	学術雑誌(症例報告)	A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2). 2026/06
4.	学術雑誌(症例報告)	Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer. 2026/05/24
5.	学術雑誌(症例報告)	APGOT Investigators. Equitable authorship in Global Gynecologic Oncology trials: the Asia Pacific Gynecologic Oncology Trials Group (APGOT) framework. 2026/05/21
6.	学術雑誌(症例報告)	ENGOT-ov65/KEYNOTE-B96 investigators. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. 2026/04/18
7.	学術雑誌(症例報告)	Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. 2026/04/12
8.	学術雑誌(症例報告)	Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025). 2026/04
9.	学術雑誌(症例報告)	Real-World Safety and Effectiveness of Rivaroxaban in Cancer-Associated Venous Thromboembolism (PRIMECAST)　- A Prospective Multicenter Study. 2026/03/25
10.	学術雑誌(症例報告)	Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial. 2026/03
11.	学術雑誌(症例報告)	Direct comparison of 5-aminolevulinic acid photodynamic diagnosis and white light inspection for detecting peritoneal dissemination in advanced ovarian cancer: a pilot study. 2026/02/26
12.	学術雑誌(症例報告)	Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results. 2026/01
13.	学術雑誌(症例報告)	First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial. I 2026/01
14.	学術雑誌(症例報告)	Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models. 2025/11
15.	学術雑誌(症例報告)	Identification of novel gene fusions in high-grade serous ovarian carcinoma: implications for tumorigenesis and targeted therapy. 2025/11
16.	学術雑誌(症例報告)	Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. 2025/09
17.	学術雑誌(症例報告)	BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis. 2025/07
18.	学術雑誌(症例報告)	Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis. 2025/07
19.	学術雑誌(症例報告)	BioBank Japan Project; NCBN Controls WGS Consortium. Impact of germline variants on breast and ovarian cancer risk in Japanese women: an original cohort study and meta-analysis. 2025/06
20.	学術雑誌(症例報告)	DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients. 2025/06
21.	学術雑誌(症例報告)	Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling. 2025/06
22.	学術雑誌(症例報告)	Histone deacetylase 6 and programmed death ligand-1 expressions after neoadjuvant chemotherapy are upregulated in patients with ovarian high-grade serous carcinoma. 2025/06
23.	学術雑誌(原著)	What can cause cancer patients to attempt suicide? Thiamine deficiency mimicking the symptoms of major depressive disorder. 2024/02/22
24.	学術雑誌(原著)	Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial 2024/02/01
25.	学術雑誌(原著)	Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer 2024/01/19
26.	学術雑誌(原著)	Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. Oncologist. 2024/01/05
27.	学術雑誌(原著)	Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer 2023/12/22
28.	学術雑誌(原著)	KEYNOTE-826 Investigators. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. 2023/12/20
29.	学術雑誌(原著)	NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer. 2023/08/19
30.	学術雑誌(原著)	Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy 2023/06/13
31.	学術雑誌(原著)	Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial 2023/05/20
32.	学術雑誌(原著)	Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial. 2023/05/02
33.	学術雑誌(原著)	Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 2023/04/24
34.	学術雑誌(原著)	Cancer Susceptibility Gene 1 (BRCA1) Germline Mutation. Cureus. 2023/03/08
35.	学術雑誌(原著)	Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. 2022/10/26
36.	学術雑誌(原著)	Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826. 2022/09/15
37.	学術雑誌(原著)	Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study. 2022/06/15
38.	学術雑誌(原著)	Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. 2022/04/23
39.	学術雑誌(原著)	Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer. 2022/04/21
40.	学術雑誌(原著)	Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer 2022/02/23
41.	学術雑誌(原著)	Survival with Cemiplimab in Recurrent Cervical Cancer. 2022/02/10
42.	学術雑誌(原著)	Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma 2022/01/13
43.	学術雑誌(原著)	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). 2021/11/20
44.	学術雑誌(原著)	Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. 2021/11/19
45.	学術雑誌(原著)	Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. 2021/11/11
46.	学術雑誌(原著)	Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. 2021/07/15
47.	学術雑誌(原著)	Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. 2021/06/01
48.	学術雑誌(原著)	Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer 2021/03
49.	学術雑誌(原著)	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer 2020/12/10
50.	学術雑誌(原著)	Immunogenomic landscape of gynecologic carcinosarcoma 2020/12/06
51.	学術雑誌(原著)	Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma 2020/10/28
52.	学術雑誌(原著)	A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer 2020/03
53.	学術雑誌(原著)	Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100 2020/02
54.	学術雑誌(総説)	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management 2018/11
55.	学術雑誌(原著)	Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element 2018/09
56.	学術雑誌(症例報告)	Subclinical thiamine deficiency identified by preoperative evaluation in a patient with rapidly growing ovarian cancer: Diagnosis and the need for preoperative thiamine measurement. 2018/08/31
57.	学術雑誌(原著)	Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma 2018/05
58.	学術雑誌(原著)	Phase I Study of Multiple Epitope Peptide Vaccination in Patients with Recurrent or Persistent Cervical Cancer 2018/05
59.	学術雑誌(原著)	Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer 2018/05
60.	学術雑誌(原著)	Association of histone deacetylase expression with histology and prognosis of ovarian cancer 2018/03
61.	学術雑誌(原著)	Significance of venous thromboembolism in women with uterine carcinosarcoma 2018/02
62.	学術雑誌(原著)	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells 2018/01
63.	学術雑誌(原著)	Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations 2017/12
64.	学術雑誌(原著)	Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression. 2017/07
65.	学術雑誌(原著)	The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma 2017/06
66.	学術雑誌(原著)	Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer 2017/05
67.	学術雑誌(原著)	Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy. 2017/04
68.	学術雑誌(原著)	Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. 2017/01
69.	学術雑誌(原著)	T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer 2016/12
70.	学術雑誌(原著)	MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53 2016/11
71.	学術雑誌(原著)	Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study 2016/10
72.	学術雑誌(原著)	Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma 2016/07
73.	学術雑誌(症例報告)	Advanced Mucinous Adenocarcinoma Arising from a Mature Cystic Teratoma: A Case Report and Literature Review． 2016/06
74.	学術雑誌(原著)	Utility of histogram analysis of apparent diffusion coefficient maps obtained using 3.0T MRI for distinguishing uterine carcinosarcoma from endometrial carcinoma. 2016/06
75.	学術雑誌(原著)	Contributing factors for menopausal symptoms after surgical staging for endometrial cancer 2016/05
76.	学術雑誌(原著)	The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin. 2016/03
77.	学術雑誌(原著)	Serum folate receptor alpha (FRA) as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression 2015/12
78.	学術雑誌(原著)	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. 2015/09
79.	学術雑誌(原著)	Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas. 2015/07
80.	学術雑誌(原著)	The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients 2015/05
81.	学術雑誌(原著)	A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors. 2015/04
82.	学術雑誌(原著)	Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing 2015/04
83.	学術雑誌(原著)	Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. 2015/02
84.	学術雑誌(症例報告)	Synchronous mucinous metaplasia and neoplasia of the female genital tract with external urethral meatus neoplasm: A case report. 2015/02
85.	学術雑誌(原著)	Feasibility Study of Combination Chemotherapy with Paclitaxel, Doxorubicin and Cisplatin without Prophylactic Granulocyte Colony-stimulating Factor Injection for Intermediate-to-high Risk or Recurrent Endometrial Cancer. 2014/11
86.	学術雑誌(総説)	Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. 2014/11
87.	学術雑誌(原著)	Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. 2014/05
88.	学術雑誌(原著)	Antibody-Based Tumor Vascular Theranostics Targeting the Human Endosialin/TEM1 In Vivo 2014
89.	学術雑誌(原著)	Development, Optimization, and Validation of Novel anti-TEM1/CD248 Affinity Agent for Optical Imaging in Cancer 2014
90.	学術雑誌(原著)	Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial 2014
91.	学術雑誌(原著)	Estrogen Receptor Expression and Increased Risk of Lymphovascular Space Invasion in High-grade Serous Ovarian Carcinoma 2014
92.	学術雑誌(原著)	Estrogen-producing endometrioid adenocarcinoma resembling sex cord-stromal tumor of the ovary: a review of four postmenopausal cases. 2012/11
93.	学術雑誌(総説)	子宮肉腫の臨床像と治療 2012/10
94.	学術雑誌(原著)	Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study. 2012/01
95.	学術雑誌(症例報告)	Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings. 2010/12
96.	学術雑誌(原著)	Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers. 2010/08
97.	学術雑誌(原著)	少量のPaclitaxelを併用したCarboplatin療法の検討 2010/07
98.	学術雑誌(原著)	プラチナ/タキサン抵抗性卵巣癌に対するネダプラチン単剤治療の有効性の検討 2010/04
99.	学術雑誌(原著)	PSMAを標的とし麻疹ウイルスを利用した前立腺がんに対するウイルス治療 2009/07
100.	学術雑誌(総説)	卵巣境界悪性腫瘍の妊孕能温存治療 2009/04
5件表示
全件表示(100件)

■ 学会発表

1.	HDAC6 as a therapeutic target for ovarian clear cell carcinoma, in association with ARID1A loss （ポスター，一般） 2018/09/16
2.	Soluble folate receptor alpha as a biomarker for epithelial ovarian cancer （口頭発表，一般） 2013/10/02
3.	Redirected antitumor activity of an engineered Sendai virus vector in ovarian cancer cells （ポスター，一般） 2013/02/22
4.	Tumor Board I: Clear cell carcinoma of the uterus （口頭発表，一般） 2012/10/14
5.	Soluble MUC1 as a Biomarker for Epithelial Ovarian Cancer （ポスター，一般） 2012/10/13
6.	Soluble folate receptor alpha as a biomarker for epithelial ovarian cancer （ポスター，一般） 2012/09/21
7.	Soluble mesothelin related peptide as a theranostic marker for ovarian cancer （ポスター，一般） 2012/09/21
8.	The use of an engineered sendai virus in urokinase-type plasminogen activator targeted therapy of ovarian cancer （口頭発表，一般） 2012/09/19
9.	卵巣がんに対するuPA標的化センダイウイルスを利用した新規治療法の開発（口頭発表，一般） 2012/06/23
10.	子宮体部間葉系腫瘍〜Clinical Management of Uterine Sarcomas〜（口頭発表，一般） 2012/06/16
11.	婦人科がんに対するメトロノミック化学療法のエビデンス構築に向けて（口頭発表，一般） 2012/05/25
12.	卵巣がんに対するurokinase-type plasminogen activator感応性細胞融合能を持ったセンダイウイルスベクターの抗腫瘍効果の検討（ポスター，一般） 2012/04/14
13.	Peglayted Liposomal Doxorubicin Augments The Efficacy Of Engineered Human T Cells Expressing A p53-specific T Cell Receptor Against Ovarian Cancer （ポスター，一般） 2012/03/24
14.	がん薬物療法のバイオマーカー•婦人科がん（口頭発表，一般） 2011/10/27
15.	健常人末梢血単核球を用いたカツマキソマブのin vitroにおける抗腫瘍効果の検討（口頭発表，一般） 2011/07/23
16.	婦人科悪性腫瘍と静脈血栓症（口頭発表，一般） 2011/06/20
17.	婦人科がんに対する維持化学療法のエビデンス構築に向けて（口頭発表，一般） 2011/01/22
18.	上皮性卵巣癌に対するCarboplatin腹腔内投与及びPaclitaxel腹腔内/静脈内点滴投与の併用療法のFeasibility Study （口頭発表，一般） 2010/07/09
19.	子宮体癌術前Ｔ１ｂ期に対するリンパ節郭清の必要性について（口頭発表，一般） 2010/07/09
20.	子宮体部病変に対するＭＲＩ拡散強調画像を用いたＡＤＣ値の有用性の検討（ポスター，一般） 2010/04/24
21.	子宮頸部扁平上皮癌での化学放射線療法の効果判定における拡散強調画像の有用性の検討（口頭発表，一般） 2009/10/24
22.	腹腔内化学療法卵巣癌における腹腔内化学療法の概説（口頭発表，一般） 2009/10/23
23.	上皮性卵巣癌に対するパクリタキセル/カルボプラチン腹腔内投与を含むTC療法の予備試験（ポスター，一般） 2009/07/11
24.	子宮頸部腺癌症例でのneoadjuvant chemothrapyの効果判定における拡散強調画像の有用性の検討（口頭発表，一般） 2009/07/11
5件表示
全件表示(24件)

■ 専門医・専門性キーワード

専門医取得の有無：有り
婦人科腫瘍
がん免疫
臨床開発
トランスレーショナルリサーチ
バイオマーカー